CSIMarket
 
Gsk Plc  (GSK)
Other Ticker:  
 
 
Price: $42.1900 $-0.89 -2.066%
Day's High: $42.43 Week Perf: -1.7 %
Day's Low: $ 41.81 30 Day Perf: 0.93 %
Volume (M): 4,130 52 Wk High: $ 43.84
Volume (M$): $ 174,245 52 Wk Avg: $36.82
Open: $42.28 52 Wk Low: $33.33



 Market Capitalization (Millions $) 172,308
 Shares Outstanding (Millions) 4,084
 Employees 99,437
 Revenues (TTM) (Millions $) 29,324
 Net Income (TTM) (Millions $) 15,621
 Cash Flow (TTM) (Millions $) 3,723
 Capital Exp. (TTM) (Millions $) 1,143

Gsk Plc
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company that was formed in December 2000 by the merger of Glaxo Wellcome plc and SmithKline Beecham plc. It is headquartered in London, United Kingdom and has operations in more than 150 countries with a presence in both developed and developing economies. The company specializes in the discovery, development, manufacturing, and marketing of prescription drugs, vaccines, over-the-counter (OTC) medicines, and health-related consumer products.

The companyes portfolio is focused on 3 main areas: Pharmaceuticals, Vaccines and Consumer Healthcare. GSKes Pharmaceutical segment offers a wide range of drugs that aim to cure, treat or prevent diseases in different therapeutic areas like cancer, respiratory, cardiovascular and metabolic diseases. Some of the most popular drugs that they produce include Advair, Flovent, Augmentin, Tivicay and Relvar/Breo. The Vaccines segment offers a broad range of preventive vaccines for infectious diseases like meningitis, hepatitis A and B, HPV and flu. Finally, the Consumer Healthcare segment provides OTC medicines, vitamins, supplements, and oral care products such as Aquafresh and Sensodyne.

GSK employs approximately 95,000 people worldwide, with a diverse mix of ethnicities, cultures, and backgrounds. Diversity and inclusion are a key focus for the company, and they have established several programs to promote gender equality, LGBTQ+ rights, and provide equal opportunities for underrepresented communities.

In recent years, GSK has made several acquisitions and divestitures to streamline its operations, including the exit of their oncology business, the acquisition of Novartis' consumer healthcare unit, and the formation of a joint venture with Pfizer for their consumer healthcare business. The company has also invested heavily in research and development to deliver innovative products to the market. In 2020, GSK invested approximately e3.6 billion in R&D, with a focus on disease areas such as HIV/AIDS, respiratory, and oncology.

As a global healthcare leader, GSK has been recognized for its commitment to sustainability and corporate social responsibility. The company has set ambitious targets to reduce its environmental impact, including pledging to be carbon neutral by 2050. GSK has also established various programs focused on improving global health and access to healthcare through initiatives like its global partnership with Save the Children to protect children from preventable diseases.

Overall, GlaxoSmithKline is an innovative pharmaceutical company that is dedicated to developing and delivering innovative medicines and products that improve the health and well-being of people worldwide. Through its commitment to sustainability, diversity, and social responsibility, the company aims to make a positive impact on the world.


   Company Address: 980 Great West Road, Brentford Middlesex 0
   Company Phone Number: 8047 5000   Stock Exchange / Ticker: NYSE GSK
   


Customers Net Income fell by GSK's Customers Net Profit Margin fell to

-8.6 %

3.13 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
LLY        1.02% 
PFE   -1.04%    
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Gsk Plc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com